Interest of a computerized ALS database in the diagnosis and follow-up of patients with ALS;Interets d'une base de donnees informatisee dans le diagnostic et le suivi de patients atteints de sclerose laterale amyotrophique

Revue Neurologique

Volumn 156, Issue 4, 2000, Pages 357-363

  Couratier, P ^c   Druet Cabanac, M ^a   Truong, C T ^c   Bernet Bernady, P ^c   Dumas, M ^c   Vallat, J M ^c   Preux, P M ^b  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF LIMOGES   (France)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

RILUZOLE; NEUROPROTECTIVE AGENT;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; COMPUTER PROGRAM; DATA BASE; DISABILITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR NEURON DISEASE; SURVIVAL RATE; TREATMENT OUTCOME; BRAIN; COMPUTER ASSISTED DIAGNOSIS; HOSPITALIZATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; STATISTICS;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN; DATABASES; DIAGNOSIS, COMPUTER-ASSISTED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROPROTECTIVE AGENTS; RILUZOLE; SEVERITY OF ILLNESS INDEX;

EID: 0034061680     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group (1996). The amyotrophic lateral sclerosis functional rating scale: Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol, 53: 141-147.
2. ALS CNTF Treatment Study Group (1996). A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rhCNTF) in amyotrophic lateral sclerosis. Neurology, 46: 1244-1249.
3. ASHWORTH B. (1964). Trial of carisoprodol in multiple sclerosis. Practionner, 192: 540-542.
4. BENSIMON G, LACOWBLEZ L, MEININGER V, ALS Riluzole Study Group. (1994). A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. New Engl. J. Med, 330: 585-591.
5. BERGNER M, BOBBITT RA, CARTER WB et al. (1981). The sickness impact profile: Development and final revision of a health status measure. Med Care, 19: 787-805.
6. BORASIO GD, ROBBERRECHT W, LEIGH PN, EMILE J, GUILOFF RJ, JERUSALEM F, SILANI V, Pos PE, WOKKE JHJ, DOBBINS T. (1998). A placebo-controlled trial of insulin-like growth factor-1 in amyotrophic lateral sclerosis. Neurology, 51: 583-586.
7. BROOKS BR, LEWIS DH, RAWLING JD, SANJAK M, BELDEN DS, HAKIM H, TAN YD, SUFIT RL, GAFFNEY JM, DEPAUL R. (1994). The natural history of ALS. Williams AC (Eds.), Motor Neuron Disease, pp 131-170. Chapman & Hall, London
8. BROOKS BR, SHODIS KA, LEWIS DH, RAWLING JD, SANJAK M, BELDEN DS, HAKIM H, TAN YD, GAFFNEY JM. (1995). Natural history of amyotrophic lateral sclerosis. Quantification of symptoms, signs, strength and function. In Serratrice G, Munsat T (Eds.), Pathogenesis and therapy of amyotrophic lateral sclerosis, Advances in Neurology, Vol 68, pp 163-184. Lippincott-Raven, Philadelphia.
9. CEDARBAUM JM, STAMBLER N, BROOKS BR, BRADLEY W. (1998). Brain-derived neurotrophic factor in amyotrophic lateral sclerosis: A failed drug or a failed trial. Annals of Neurology, 44: 506-507.
10. CHAZOT F, VALLAT JM, HUGON J, LUBEAU M, DUMAS M. (1986). Amyotrophic lateral sclerosis in Limousin (Limoges area, France). Neuroepidemiology, 5: 39-46.
11. CHAZOT F, TABARAUD F, BOULESTEIX JM, HUGON J, VALLAT JM, DUMAS M. (1989). Epidemiology of amyotrophic lateral sclerosis in Limousin area. Rev Neurol, 145: 408-410.
12. COURATIER P, YI FH, PREUD'HOMME JL, CLAVELOU P, WHITE A, SINDOU P, VALLAT JM, JAUBERTEAU MO. (1998). Serum autoantibodies to neurofilament proteins in sporadic lateral sclerosis. J Neural Sci, 154: 137-145.
13. GUYATT GH, FEENY DH, PATRICK DL (1993). Measuring health-related quality of life. Ann Intern Med, 118: 622-629.
14. HAVERKAMP LJ, APPEL V, APPEL SH. (1995). Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain, 118: 707-715.
15. HAVERKAMP LJ, APPELV, APPEL SH. (1995). Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain, 118: 707-715.
16. HAVERKAMP LJ, APPEL V, APPEL SH. (1995). Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain, 118: 707-715.
17. LACOMBLEZ L, BENSIMON G, LEIGH PN, GILLET P, MEININGER V. Amyotrophic Lateral Sclerosis/Riluzole Study Group II (1996). Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet, 347: 1425-1431.
18. LAI EC, FELICE BW, GAWEL MJ, GELINAS DF, KRATZ R, MURPHY MF, NATTER HW, NORRIS FH, RUDNICKI SA (1997). Effect of recombinant human insulin-like growth factor-1 on progression of ALS. A placebo-controlled study. Neurology, 49: 1621-1630.
19. Medical Research Council: Aid to the investigation of peripheral nerve injuries (1943). War Memorandum, ed 2 (revised). His Majesty's Stationnery Office, London pp 11-46.
20. MUNSAT TL, ANDRES PL, FINISON L, CONLON T, THIBODEAU L. (1988). The natural history motoneuron loss in amyotrophic lateral sclerosis. Neurology, 38: 409-413.
21. MUNSAT TL, ANDRES PL, SKERRY L. (1990). Therapeutic trials in amyotrophic lateral sclerosis: Measurement of clinical deficit. In Rose, FC (ed)/ Amyotrophic Lateral Sclerosis Demos, New-York pp 65-76.
22. NORRIS FH, JR. (1990). Changing the course in amyotrophic lateral sclerosis. In Rose, FC (ed): Amyotrophic lateral sclerosis. Demos, New-York pp 83-92.
23. PREUX PM, COURATIER P, BOUTROS-TONI F, SALLE JY, TABARAUD F, BERNET-BERNADY P, VALLAT JM, DUMAS M. (1996). Survival prediction in sporadic amyotrophic lateral sclerosis. Age and clinical forms at onset are independant risk factors. Neuroepidemiology, 15: 153-160.
24. RIVIERE M, MEININGER V, ZEISSER P, MUNSAT T. (1998). An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol, 55: 526-528.
25. The World Federation Of Neurology Research Group On Neuromuscular Diseases Subcommittee On Motor Neuron Disease: Airlie House (1994): El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci, 124 (suppl.): 96-107.